US 12,440,571 B2
Immune agonists
Guangyi Jin, Guangdong (CN); Zhulin Wang, Guangdong (CN); Ji Zhou, Guangdong (CN); Mian Qin, Guangdong (CN); Sumei Ren, Guangdong (CN); Yajuan Cheng, Guangdong (CN); and Shuxian Tan, Guangdong (CN)
Assigned to SHENZHEN UNIVERSITY, Guangdong (CN); and SHENZHEN CONJUGENIX PHARMACEUTICAL TECHNOLOGY COMPANY LIMITED, Guangdong (CN)
Appl. No. 17/632,420
Filed by SHENZHEN UNIVERSITY, Guangdong (CN); and SHENZHEN CONJUGENIX PHARMACEUTICAL TECHNOLOGY COMPANY LIMITED, Guangdong (CN)
PCT Filed Dec. 7, 2020, PCT No. PCT/CN2020/134260
§ 371(c)(1), (2) Date Feb. 2, 2022,
PCT Pub. No. WO2021/208459, PCT Pub. Date Oct. 21, 2021.
Claims priority of application No. 202010299076.4 (CN), filed on Apr. 15, 2020; and application No. 202010595158.3 (CN), filed on Jun. 24, 2020.
Prior Publication US 2023/0108709 A1, Apr. 6, 2023
Int. Cl. A61K 47/55 (2017.01); A61K 47/62 (2017.01); A61P 37/04 (2006.01); C07D 487/04 (2006.01); C07D 519/00 (2006.01); C07F 9/6561 (2006.01); C07F 9/6584 (2006.01)
CPC A61K 47/55 (2017.08) [A61K 47/62 (2017.08); A61P 37/04 (2018.01); C07D 487/04 (2013.01); C07D 519/00 (2013.01); C07F 9/65616 (2013.01); C07F 9/65846 (2013.01)] 15 Claims
 
1. A compound having a structure represented by Formula I:

OG Complex Work Unit Chemistry
wherein
R1 represents any one of the following alkoxy groups and alkylamino groups:

OG Complex Work Unit Chemistry
L represents a connection chain, and the connection chain comprises any one of a polyethylene glycol chain, an alkyl chain, and a heterocyclic chain;
n represents an integer between 1 and 20;
R2 represents a functional group or a functional carrier;
the functional group comprises at least one of a carboxyl group, a phosphate group, an amino group, an isothiocyano group, an isocyanate group, a thiourea group, an azide group, an unsaturated double bond, and an unsaturated triple bond; or consists of at least one of a targeted drug or a precursor thereof, a protein, a polypeptide, an antibody, a virus, a bacteria, and a cell; and
the functional carrier comprises: a biocompatible material capable of binding the Formula I, a carrier capable of binding the Formula I, a biocompatible material capable of supporting the Formula I, and a carrier capable of supporting the Formula I.